Skip to main content
. 2020 Jan 16;5(1):e132522. doi: 10.1172/jci.insight.132522

Figure 6. Therapeutic treatment with BAF312 reduces TLT area and the number of B and T cells in the meninges of A/T SJL/J EAE mice.

Figure 6

(A–C) HE staining of brain sections from naive mice and A/T SJL/J EAE mice at day 11 (acute phase) treated with either vehicle control (CMC) or BAF312. (D–G) Immunofluorescent staining and quantitative analysis for the extracellular matrix protein fibronectin in brain sections from naive mice and A/T SJL/J EAE mice at day 11 (acute phase) treated with either vehicle control (CMC) or BAF312. (H–K) Immunofluorescence staining and quantitative analysis for B220+ B cells in brain sections from naive mice and A/T SJL/J EAE mice at day 11 (acute phase) treated with either vehicle control (CMC) or BAF312. (L–O) Immunofluorescence staining and quantitative analysis for CD3+ T cells in brain sections from naive mice and A/T SJL/J EAE mice at day 11 (acute phase) treated with either vehicle control (CMC) or BAF312. (P–R) Merged images of H–J and L–N. M, meninges. For all quantifications, values are shown as mean ± SEM, and statistical analysis was done by Mann-Whitney U test. Scale bars: 50 μm.